Last $16.44 USD
Change Today +0.96 / 6.20%
Volume 286.0K
As of 12:44 PM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).

regulus therapeutics inc (RGLS) Snapshot

Open
$15.78
Previous Close
$15.48
Day High
$16.53
Day Low
$15.71
52 Week High
11/10/14 - $25.60
52 Week Low
05/9/14 - $5.40
Market Cap
799.0M
Average Volume 10 Days
442.2K
EPS TTM
$-0.92
Shares Outstanding
48.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REGULUS THERAPEUTICS INC (RGLS)

regulus therapeutics inc (RGLS) Related Businessweek News

View More BusinessWeek News

regulus therapeutics inc (RGLS) Details

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs for the treatment of various diseases in the United States. The company uses its microRNA product platform to develop anti-miRs, which is chemically modified and single-stranded oligonucleotide. Its clinical candidate products include RG-101, which is a GalNAc-conjugated anti-miR that targets microRNA-122 for the treatment of patients with chronic hepatitis C virus infection. The company has strategic collaboration with Biogen Idec MA Inc. for the evaluation of the use of microRNA signatures as a biomarker for human patients with multiple sclerosis; AstraZeneca AB to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases, and oncology; and GlaxoSmithKline plc to discover and develop microRNA therapeutics for immuno-inflammatory diseases. It also has strategic collaboration with Sanofi for the discovery and development of microRNA therapeutics comprising miR-21 pre-clinical fibrosis program for the treatment of alport syndrome and preclinical program for oncology indications; and preclinical programs targeting miR-221/222 for oncology indications. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.

81 Employees
Last Reported Date: 08/7/14
Founded in 2007

regulus therapeutics inc (RGLS) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $600.0K
Chief Scientific Officer
Total Annual Compensation: $350.0K
Compensation as of Fiscal Year 2013.

regulus therapeutics inc (RGLS) Key Developments

Regulus Therapeutics Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 02:00 PM

Regulus Therapeutics Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 02:00 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Kleanthis G. Xanthopoulos, Chief Executive Officer, President, Principal Financial & Accounting Officer and Director.

Regulus and Sanofi Present New Data Enhancing the Preclinical Profile of RG-012, an Anti-miR Targeting microRNA-21 for the Treatment of Renal Dysfunction in Alport Syndrome Patients, at ASN's Kidney Week 2014 Meeting

Regulus Therapeutics Inc. announced that positive new preclinical data was presented on RG-012 for the treatment of renal dysfunction in Alport syndrome patients at the American Society of Nephrology's (ASN) Kidney Week 2014 meeting being held November 11-16, 2014 in Philadelphia, PA. Alport syndrome is a life-threatening, genetic kidney disease with no approved therapy, and currently, ACE (angiotensin-converting enzyme) inhibitors are emerging as standard of care to treat proteinuria, an indicator of chronic kidney disease (CKD) in these patients. Studies have shown that miR-21 plays a role in the progression of Alport syndrome and is up-regulated in mouse disease models, other renal fibrosis models and human CKD patients. These findings, and the new preclinical data presented at the ASN meeting, provide additional evidence that RG-012 may provide therapeutic benefit in the treatment of Alport syndrome. In an oral presentation titled "Anti-miR-21 as a Potential Novel Therapy for Both Early and Late Stages of Alport Syndrome", Regulus' strategic alliance partner, Genzyme, a Sanofi company, presented new data demonstrating that treatment with RG-012 in a mouse model of disease improves renal function, protects against kidney damage and extents the lifespan of the mice when treatment begins at both early and late stages of the disease by reversing multiple dysregulated pathways. Further, combination studies were performed with RG-012 and ramipril, Sanofi's ACE inhibitor, a kidney protectant, to assess the therapeutic utility of adding a microRNA therapeutic to this emerging standard of care. In these preclinical studies, treatment with RG-012 was shown to protect kidney function better than ramipril alone and an additive therapeutic effect was observed in combination with ramipril.

Regulus Therapeutics Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Full Year 2014

Regulus Therapeutics Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenue of $1.083 million compared to $6.118 million a year ago. Loss from operations was $11.659 million compared to $2.905 million a year ago. Loss before income taxes was $9.798 million compared to $2.169 million a year ago. Net loss was $9.798 million or $0.26 per diluted share compared to $2.164 million or $0.07 per diluted share a year ago. Consistent with prior periods revenues primarily reflect the amortization of upfront payments received from strategic alliances and collaborations which was recognized over the estimated period of performance. For the nine months, the company reported total revenue of $3.450 million compared to $14.115 million a year ago. Loss from operations was $35.377 million compared to $13.140 million a year ago. Loss before income taxes was $34.511 million compared to $16.745 million a year ago. Net loss was $34.512 million or $0.80 per diluted share compared to $16.741 million or $0.45 per diluted share a year ago. The company also increased year-end guidance to end 2014 with now greater than $150 million in cash.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGLS:US $16.48 USD +1.00

RGLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Benitec Biopharma Ltd A$0.84 AUD -0.03
Galena Biopharma Inc $1.60 USD -0.03
Prosensa Holding NV $18.76 USD +0.28
Silence Therapeutics PLC 205.00 GBp +5.00
Tekmira Pharmaceuticals Corp C$16.30 CAD +0.08
View Industry Companies
 

Industry Analysis

RGLS

Industry Average

Valuation RGLS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 48.1x
Price/Book 8.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 45.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGULUS THERAPEUTICS INC, please visit www.regulusrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.